Veracyte stock faces Decipher reset as spending plans rise
Published on 11/20/2026 at 01:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSVeracyte resets its growth path
- Management said Decipher growth is normalizing after a period of unusually strong guideline-driven demand.
- Afirma, Prosigna and newer tests are becoming more important to the companys portfolio.
- Veracyte expects investment to weigh on adjusted EBITDA margins in 2027 before a recovery in 2028.
Veracyte management used the Stephens Annual Investment Conference on Thursday, November 19, to outline a more cautious outlook for its Decipher prostate cancer test while emphasizing growth from a broader diagnostics portfolio. A transcript published by Investing.com said management had lowered its expectations after Decipher reports came in 1,000 below quarterly expectations.
Management attributed the reset to normalization after unusually strong growth in 2023 and 2024, slower adoption in some low-risk settings and competition from digital pathology providers. The company views 12,000 incremental annual Decipher cases as a floor, with potential upside toward 15,000 as sales execution improves and additional clinical evidence supports adoption.
Investment weighs on near-term margins
Veracyte plans to raise sales and marketing spending for Decipher by 30 percent, while continuing to invest in Prosigna, research and development and newer products. Management expects adjusted EBITDA margin to ease to about 22 percent in 2027 and said the business could return to margins above 25 percent in 2028 if execution remains on track.
The company said Afirma volume growth remains constructive, while Prosigna is building an initial base among ordering institutions. The publication of results from the OPTIMA trial in 2027 and potential changes to treatment guidelines are described as important catalysts for the breast cancer test.
Late Thursday trading
Veracyte stock traded at 23.18 euros on Lang & Schwarz at 23:00 CET on Thursday, November 19. The quote was 0.01 euros above the previous close shown for the same trading venue.
Business and competitive position
Veracyte develops cancer diagnostics that support treatment decisions across prostate, thyroid and breast cancer, including Decipher, Afirma and Prosigna. The company is expanding from a concentrated product base toward a multi-test portfolio that also includes newer offerings such as TrueMRD and urology assets. Its commercial focus is the US diagnostics market, with clinical evidence, reimbursement and physician adoption shaping demand.
Veracyte company facts
- Company: Veracyte, Inc.
- ISIN: US92337F1075
- Ticker: VCYT
- Home exchange: Nasdaq
- Lang & Schwarz quote: 23.18 euros at 23:00 CET on November 19, 2026
- Previous close: 23.17 euros
- Market capitalization: 2,020,614,819 US dollars as of November 19, 2026
US equity markets provide the broader setting for Veracyte through the S&P 500 market environment.
For more news and analyses on Veracyte stock, follow the company topic page.
